Next Article in Journal
Comparison of Chemical Composition and Biological Activities of Eight Selaginella Species
Next Article in Special Issue
COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection
Previous Article in Journal
Multifunctional Delivery Systems for Peptide Nucleic Acids
Previous Article in Special Issue
Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules
Perspective

Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19

by 1,2,* and 1,2
1
Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia
2
Australian Institute for Musculoskeletal Science, St Albans, VIC 3021, Australia
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(1), 15; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010015
Received: 14 November 2020 / Revised: 23 December 2020 / Accepted: 23 December 2020 / Published: 26 December 2020
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and oxidative stress that can lead to death. Given the shared pathogenesis of severe cases of COVID-19 with aspects of multiple sclerosis and psoriasis, we propose dimethyl fumarate as a viable treatment option. Currently approved for multiple sclerosis and psoriasis, dimethyl fumarate is an immunomodulatory, anti-inflammatory and anti-oxidative drug that could be rapidly implemented into the clinic to calm the cytokine storm which drives severe COVID-19. View Full-Text
Keywords: COVID-19; dimethyl fumarate; Nrf2; therapeutics COVID-19; dimethyl fumarate; Nrf2; therapeutics
Show Figures

Graphical abstract

MDPI and ACS Style

Timpani, C.A.; Rybalka, E. Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19. Pharmaceuticals 2021, 14, 15. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010015

AMA Style

Timpani CA, Rybalka E. Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19. Pharmaceuticals. 2021; 14(1):15. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010015

Chicago/Turabian Style

Timpani, Cara A., and Emma Rybalka. 2021. "Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19" Pharmaceuticals 14, no. 1: 15. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010015

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop